[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565975":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":43,"collaborators":7,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":7,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":7,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Shin-young Oh","CONTACT","+82-2-708-8000","syoh@boryung.co.kr",[15,31],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":7,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Andong Hospital","RECRUITING","Andong","Gyeongsangbuk-do","36743","South Korea",{"type":23,"coordinates":24},"Point",[25,26],128.72275,36.56636,{"lat":26,"lon":25},[29],{"name":30,"role":11,"phone":7,"phoneExt":7,"email":7},"Joong-kyung Sung",{"facility":32,"status":33,"city":34,"state":7,"zip":7,"country":21,"countryCode":7,"cosmosGeoPoint":35,"geoPoint":39,"contacts":40},"Konkuk University medical center","NOT_YET_RECRUITING","Seoul",{"type":23,"coordinates":36},[37,38],126.9784,37.566,{"lat":38,"lon":37},[41],{"name":42,"role":11,"phone":7,"phoneExt":7,"email":7},"Kee-ho Song",{"type":44,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100565975","a-study-to-identify-the-risk-of-non-alcoholic-fatty-liver-disease-nafld-in-patients-with-type-2-diabetes-in-clinical-practice-and-to-evaluate-the-clinical-usefulness-of-dapagliflozinpioglitazone-combination-therapy-100565975",false,"NCT06649162","A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin\u002FPioglitazone Combination Therapy","A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin\u002FPioglitazone Combination Therapy","Inclusion Criteria:\n\n* Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin\u002Fpioglitazone at baseline (visit 1)\n* Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.\n\nExclusion Criteria:\n\n* Those who have a history of taking a fixed-dose combination of dapagliflozin\u002Fpioglitazone at baseline (visit 1).\n* Those who are expected to need insulin prescription during the study period.","ALL","19 Years",{"count":55,"type":56},10000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin\u002FPioglitazone combination therapy",[60],"Type 2 Diabetes","2024-10-17",{"date":63,"type":64},"2024-10-18","ACTUAL",{"date":66,"type":64},"2024-09-30",{"date":68,"type":56},"2027-03",{"name":5,"class":6},2]